NEW YORK, Nov. 20, 2017 /PRNewswire/ --
If you want a Stock Review on PRAH, VWR, DGX, or LH then come over to http://dailystocktracker.com/register/and sign up for your free customized report. On Friday, November 17, 2017, the NASDAQ Composite ended the trading session at 6,782.79, down 0.15%; the Dow Jones Industrial Average edged 0.43% lower, to finish at 23,358.24;
PRA Health Sciences
Raleigh, North Carolina headquartered PRA Health Sciences Inc.'s stock finished Friday's session 1.00% higher at $80.70 with a total trading volume of 383,938 shares. The Company's shares have advanced 47.80% over the past twelve months and 46.41% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 1.85% and 12.90%, respectively. Additionally, shares of the Company, which provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide, have a Relative Strength Index (RSI) of 51.58. Sign up and read the free research report on PRAH at: http://dailystocktracker.com/registration/?symbol=PRAH
On Friday, shares in Radnor, Pennsylvania-based VWR Corp. recorded a trading volume of 1.08 million shares, which was above its three months average of 934.12 thousand shares. The stock ended the session flat at $33.24. The Company's shares have advanced 24.26% over the last twelve months and 32.80% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 0.33% and 5.97%, respectively. Moreover, shares of VWR Corp., which together with its subsidiaries, operates as an independent provider of laboratory products, services, and solutions to the life science, general research, and applied markets, have an RSI of 63.94. The complimentary research report on VWR can be downloaded at: http://dailystocktracker.com/registration/?symbol=VWR
Madison, New Jersey headquartered Quest Diagnostics Inc.'s shares closed the day 0.11% higher at $93.04. The stock recorded a trading volume of 2.01 million shares which was above its three months average volume of 1.23 million shares. The Company's shares have gained 8.45% over the last twelve months. The stock is trading below its 50-day moving average by 2.69%. Additionally, shares of Quest Diagnostics, which provides diagnostic testing information and services in the US and internationally, have an RSI of 43.60.
On October 20th, 2017, research firm Mizuho reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $122 a share to $103 a share. Register for free on DailyStockTracker.com and access the latest report on DGX at: http://dailystocktracker.com/registration/?symbol=DGX
Laboratory Corp. of America Holdings
Shares in Burlington, North Carolina headquartered Laboratory Corp. of America Holdings finished 0.44% lower at $150.36. The stock recorded a trading volume of 468,509 shares. The Company's shares have advanced 18.28% over the last twelve months and 17.12% on an YTD basis. The stock is trading above its 200-day moving average by 1.86%. Furthermore, shares of the Company, which operates as an independent clinical laboratory company worldwide, have an RSI of 45.14. Get free access to your research report on LH at: http://dailystocktracker.com/registration/?symbol=LH
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://dailystocktracker.com/disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: email@example.com Phone number: (207)331-3313Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/stocks-under-scanner-in-the-medical-research-space----pra-health-sciences-vwr-corp-quest-diagnostics-and-laboratory-corp-of-america-300559245.html
Subscribe to our Free Newsletters!
Sleep paralysis is a condition where one feels unable to move (paralysis) or speak either when ...
Summers days are long, hot and sweaty, and can leave you feeling de-hydrated and tired. Read on to ...
Fosnetupitant and Palonosetron (a fixed antiemetic combination) injection was approved by FDA in ...View All